Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Autoimmune disease stories

Nov 11, 2026

Amgen's Sjögren's drug cuts disease activity in trial

Amgen reported positive trial results showing its experimental drug reduced disease activity in patients with Sjögren's syndrome, a chronic autoimmune condition with limited treatment options.

Nov 11, 2026·2 sources
00
Nov 7, 2026

T-Therapeutics raises $133M Series B for T-cell therapies in cancer and autoimmune disease

UK-based T-Therapeutics closed a $133 million Series B funding round led by Advent Life Sciences and British Business Bank to advance T-cell therapies targeting cancer and autoimmune diseases.

Nov 7, 2026·2 sources
00
Oct 30, 2026

Psoriasis patients face increased cataract risk, study finds

A study published in the Journal of Dermatology found that patients with psoriasis have an increased risk for cataracts and cataract surgery, with risks varying by treatment modality. The research was conducted by Yan-Jie Su from Taipei Veterans General Hospital in Taiwan.

Oct 30, 2026·2 sources
00

FDA approves tildrakizumab for psoriatic arthritis

The FDA cleared Sun Pharma's interleukin-23 inhibitor tildrakizumab (Ilumya) for the treatment of active psoriatic arthritis in adults, expanding the drug's approved indications.

Oct 30, 2026·3 sources
00
Oct 29, 2026

Stem cell transplants show 60% progression-free survival at 10 years for severe systemic sclerosis

An international study reports 60% progression-free survival at 10 years after autologous bone marrow transplantation in patients treated for early severe systemic sclerosis, providing evidence of sustained positive clinical outcomes and long-term safety for the rare autoimmune disease.

Oct 29, 2026·3 sources
00

St. Jude researchers discover COMPASS pathway that prevents autoimmune responses to gut bacteria

Scientists at St. Jude Children's Research Hospital have identified a gene-regulatory pathway called COMPASS that enables regulatory T cells to maintain immune tolerance to trillions of bacteria in the human gut. The discovery, published in Science Advances, explains how the body prevents devastating autoimmune responses to intestinal microbes.

Oct 29, 2026·2 sources
00

Researchers link linoleic acid breakdown product to psoriasis itch through GPR35 receptor

Scientists have discovered that EKODE, a metabolite of commonly consumed linoleic acid fat, binds to the GPR35 receptor to trigger inflammation and itching in psoriasis. Blocking this receptor in mouse models significantly reduced both inflammation and scratching behavior.

Oct 29, 2026·2 sources
00
Oct 28, 2026

Scientists discover neutrophil mutations trigger autoimmune response in lupus patients

Researchers at La Jolla Institute for Immunology and University of Washington found that lupus patients have unusual mutations in neutrophils that generate novel peptides, which are recognized as foreign threats by T and B cells, driving autoimmune responses and antibody production.

Oct 28, 2026·2 sources
00
Oct 23, 2026

Three drugs show sustained kidney function benefits in IgA nephropathy trials at 2 years

Atacicept, telitacicept, and sibeprenlimab demonstrated unprecedented benefits in stabilizing kidney function in phase 3 trials for IgA nephropathy, with sustained effects at two years.

Oct 23, 2026·2 sources
00

Novartis multiple sclerosis drug remibrutinib shows weaker-than-expected relapse reduction

Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.

Oct 23, 2026·4 sources
00

UK approves Johnson & Johnson's oral psoriasis pill for moderate-to-severe plaque psoriasis

Britain's medicines regulator approved Johnson & Johnson's daily pill for adults and teenagers with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly and often itchy patches.

Oct 23, 2026·2 sources
00
Oct 22, 2026

Rituximab linked to increased inflammatory bowel disease risk in multiple sclerosis patients

A study published in JAMA Neurology found that multiple sclerosis patients treated with rituximab have an increased risk of developing inflammatory bowel disease, particularly Crohn's disease, though the absolute risk remains low. The research compared rituximab to other MS treatments.

Oct 22, 2026·2 sources
00
Oct 20, 2026

ARCTIC trial shows excellent 10-year outcomes with treat-to-target strategy in early rheumatoid arthritis

A new study from the ARCTIC trial demonstrates that patients with early rheumatoid arthritis managed with a treat-to-target strategy achieved favorable long-term outcomes over 10 years. Patients who achieved sustained remission at two years showed higher remission rates and better physical function throughout the decade-long follow-up period.

Oct 20, 2026·2 sources
00
Oct 19, 2026

New research reveals shared immune dysfunction mechanisms in allergies and autoimmune diseases

Growing evidence is challenging the traditional view that allergic and autoimmune disorders are opposing forms of immune dysfunction, with researchers uncovering shared mechanisms between the two conditions that have historically been evaluated and treated separately.

Oct 19, 2026·2 sources
00
Oct 16, 2026

Updated COVID vaccines reduce hospitalization risk for immunocompromised patients with autoimmune disease

A new study found that patients with autoimmune rheumatic disease who received updated or booster COVID-19 vaccines had significantly lower odds of COVID-related hospitalization compared to those who only received the initial vaccine series. The findings come as COVID hospitalizations have risen sharply in recent weeks.

Oct 16, 2026·2 sources
00
Oct 8, 2026

Argenx reports positive Phase 2 results for FB102 in celiac disease, plans Phase 3 trial

Argenx announced its experimental drug FB102 met the primary endpoint in a Phase 2 study for celiac disease, providing first evidence that blocking CD122 can prevent gluten-induced intestinal damage. The company plans to advance the drug into Phase 3 development, though the news was overshadowed by a simultaneous setback in Sjögren's disease that sent shares falling.

Oct 8, 2026·3 sources
00
Sep 28, 2026

FDA approves baricitinib for adolescents with severe alopecia areata

The FDA has expanded the indication for baricitinib (Olumiant), a once-daily oral JAK inhibitor, to include adolescents aged 12 and older with severe alopecia areata. This marks the second JAK inhibitor treatment approved for adolescents with the condition.

Sep 28, 2026·3 sources
00

Three deaths in Novartis CAR T-cell therapy trials for autoimmune disease prompt caution

Three participants have died in clinical trials of Novartis' chimeric antigen receptor T-cell therapy for autoimmune disease, prompting physicians to approach patient discussions with greater caution as the field remains in early stages of development.

Sep 28, 2026·3 sources
00
Sep 24, 2026

Kyverna Therapeutics reports one-year durability data for autoimmune cell therapy

Kyverna Therapeutics released one-year follow-up data showing patients with stiff person syndrome remained off other therapies after treatment with its CAR-T cell therapy miv-cel. The company plans to file for FDA priority review this year, which would make it the first cell therapy approved for an autoimmune disease.

Sep 24, 2026·4 sources
00
Sep 17, 2026

Systemic lupus erythematosus linked to increased risk for stroke

A systematic review found that systemic lupus erythematosus (SLE) is associated with an increased risk for stroke, including both ischemic and hemorrhagic stroke types.

Sep 17, 2026·1 source
00
Aug 12, 2026

Boulevard Bio launches with $65M to develop targeted autoimmune antibody therapies

Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.

Aug 12, 2026·4 sources
00
Jul 30, 2026

Pfizer's LITFULO Meets Primary Endpoints in Phase 3 Trials for Nonsegmental Vitiligo Treatment

Pfizer announced positive topline results from two pivotal Phase 3 studies showing LITFULO (ritlecitinib) significantly improved facial and total repigmentation compared to placebo at 52 weeks in patients with nonsegmental vitiligo. The studies represent the largest Phase 3 program to date for an oral systemic therapy in this indication.

Jul 30, 2026·1 source
00
Jul 27, 2026

Chinese Drugmaker Innocare Reports Positive Late-Stage Trial Results for Psoriasis Oral Treatment

Innocare Pharma announced its experimental oral drug for moderate-to-severe plaque psoriasis showed consistent treatment effects in late-stage clinical trials, entering a competitive market where recent head-to-head studies have compared efficacy of various psoriasis treatments.

Jul 27, 2026·3 sources
00
Jul 22, 2026

Biohacker Bryan Johnson Claims to Have Created Stem Cell Clone to Grow Replacement Organs

Tech entrepreneur and anti-aging advocate Bryan Johnson announced he has created what he describes as a 'newborn' version of himself using stem cells, with the goal of growing replacement organs after being diagnosed with autoimmune gastritis. The controversial experiment represents his latest effort in his 'Don't Die' longevity campaign.

Jul 22, 2026·3 sources
00

Top claims

  • ▪In the NEPTUNUS-1 trial involving 275 patients, monthly treatment with 300 mg of ianalumab led to a 1.3-point greater decrease in ESSDAI score compared with placebo from baseline to week 48
  • ▪In Amgen's late-stage trial of 648 patients with moderate-to-severe Sjögren's disease, a 1,500 mg dose of dazodalibep every four weeks lowered disease activity scores by 5.6 points over 48 weeks, compared to 3.8 points for placebo
  • ▪Both tested dosing regimens of Amgen's dazodalibep met the primary trial endpoint for Sjögren's disease, showing significant therapeutic effects as early as week four of treatment

People involved

Bryan Johnson

Subtopics

Autoimmune disease treatments10Clinical trials8Drug Policy, Pricing & Approval8Biologic therapies6Drug Approval and Clinical Trials5Immunology5Biotechnology4Drug development4Biomedical research3FDA drug approval3Medical research3Observational research3Pharmaceutical Industry3Randomized controlled trial3Biotech startup2Digestive diseases2Neurological disorders2Pharma2Rare diseases2Venture capital funding2Adaptive immune cells1Allergy and autoimmune disease shared immune mechanisms1Bioethics1Biohacking & optimization1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories